
Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Francesco Di Meo, PhD, discusses the potential efficacy of CAR T-cells targeting the immunoreceptor LILRB4 in multiple myeloma.